Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone

Pharmaceutical Research

Volumn 21, Issue 7, 2004, Pages 1146-1152

  Pillai, Omathanu ^a   Hamad, Mohamed O ^a   Crooks, Peter A ^a   Stinchcomb, Audra L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

biotransformation; human skin; naltrexone; prodrugs; transdermal drug delivery

Indexed keywords

AMYLNALTREXONE 3 O CARBONATE; BUFFER; BUTYLNALTREXONE 3 O CARBONATE; ETHYLNALTREXONE 3 O CARBONATE; ISOPROPYLNALTREXONE 3 O CARBONATE; METHYLNALTREXONE 3 O CARBONATE; MINERAL OIL; NALTREXONE DERIVATIVE; PRODRUG; PROPYLNALTREXONE 3 O CARBONATE; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG DIFFUSION; DRUG DISPOSITION; DRUG SOLUBILITY; DRUG STRUCTURE; EVALUATION; FLOW RATE; HEAT; HUMAN; HUMAN TISSUE; HYDROLYSIS; IN VITRO STUDY; MELTING POINT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SKIN PERMEABILITY; STRATUM CORNEUM; THERMODYNAMICS;

BIOTRANSFORMATION; DRUG STABILITY; EPIDERMIS; FORMATES; HUMANS; MOLECULAR WEIGHT; NALTREXONE; NARCOTIC ANTAGONISTS; PERMEABILITY; PRODRUGS; SKIN ABSORPTION; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TRANSITION TEMPERATURE;

EID: 3242700655     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000033000.03652.73     Document Type: Article

References (20)

1. J. R. Volpicelli, A. I. Alterman, and M. Hayashida. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49:876-880 (1992).
2. L. Terenius. Rational treatment of addiction. Curr. Opin. Chem. Biol. 2:541-547 (1998).
3. PDR Generics, 2nd Ed., Medical Economics, Montvale, New Jersey, 1996, pp. 2229-2233.
4. H. R. Kranzler, V. M. Lowe, and J. V Kirk. Naltrexone vs nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropyschopharmacology 22:493-503 (2000).
5. J. L. Rothenberg, M. A. Sullivan, S. H. Church, A. Seracini, E. Collins, H. D. Kleber, and E. V. Nunes. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J. Substance Abuse Treat. 23:351-360 (2002).
6. J. R. Volpicelli, K. C. Rhines, and J. S. Rhines. Naltrexone and alcohol dependence. Role of subject compliance. Arch. Gen. Psychiatry 54:737-743 (1997).
7. L. L Gooberman. Pharmaceutical delivery device and method of preparation therefor. U.S. Patent No. 6,203,813 (March 20, 2001).
8. A. Naik, Y. N. Kalia, and R. H. Guy. Transdermal drug delivery: overcoming the skin's barrier function. Pharm. Sci. Technol. Today 3:318-326 (2000).
9. Y. L. Chen, L. L Chun, and D. J. Enscore. Transdermal therapeutic systems for the administration of naloxone, naltrexone, and nalbuphine. U.S. Patent No. 4,573,995 (March 4, 1986).
10. M. A. Hussain, C. A. Koval, M. J. Myers, E. G. Shami, and E. Shefter. Improvement of the oral bioavailability of naltrexone in dogs: A prodrug approach. J. Pharm. Sci. 76:356-358 (1987).
11. M. A. Hussain, B. J. Aungst, C. A. Koval, and E. Shefter. Improved buccal delivery of opoid analgesics and antagonists with bitterless prodrugs. Pharm. Res. 5:615-618 (1988).
12. A. L. Stinchcomb, P. W. Swaan, O. Ekabo, K. E. Harris, J. Browe, D. C. Hammell, T. A. Cooperman, and M. Pearsall. Straight-chain naltrexone ester prodrugs: diffusion and concurrent biotransformation in human skin. J. Pharm. Sci. 91:2571-2578 (2002).
13. A. M. Kligman and E. Christophers. Preparation of isolated sheets of human stratum corneum. Arch. Dermatol. 88:702-705 (1963).
14. C. Surber, K. P. Wilhelm, M. Hori, H. I. Maibach, and R. H. Guy. Optimization of topical therapy: partitioning of drugs into stratum corneum. Pharm. Res. 7:1320-1324 (1990).
15. A. L. Stinchcomb, R. Dua, A. Paliwal, R. W. Woodard, and G. L. Flynn. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm. Res. 10:1526-1529 (1995).
16. W. J. Roberts and K. B. Sloan. Prediction of transdermal flux of prodrugs of 5-fluorouracil, theophylline, and 6-mercaptopurine with a series/parallel model. J. Pharm. Sci. 89:1415-1431 (2000).
17. H. D. Beall and K. B. Sloan. Transdermal delivery of 5-fluorouracil (5-FU) by 1-alkylcarbonyl-5-FU prodrugs. Int. J. Pharm. 129:203-210 (1996).
18. W. J. Roberts and K. B. Sloan. Correlation of aqueous and lipid solubilities with flux of prodrugs of 5-fluorouracil, theophylline and 6-mercaptopurine: A Potts-Guy approach. J. Pharm. Sci. 88:515-522 (1999).
19. P. Boderke, K. Schittkowsi, M. Wolf, and H. P. Merkle. Modeling of diffusion and concurrent metabolism in cutaneous tissue. J. Theor. Biol. 204:393-407 (2000).
20. S. W. Collier, N. M. Sheikh, A. Sakr, J. L. Lichtin, R. F. Stewart, and R. L. Bronaugh. Maintenance of skin viability during in vitro percutaneous absorption/metabolism studies. Toxicol. Appl. Pharmacol. 99:522-533 (1989).